跳至主要内容
临床试验/ISRCTN88858357
ISRCTN88858357已完成未知

Real-world study of the management and outcomes of patients with frontline transplant-eligible multiple myeloma in four European countries (France, Germany, Spain and Italy)

Kantar Health (France)0 个研究点目标入组 804 人开始时间: 2021年11月22日最近更新:
适应症

试验速览

阶段
未知
状态
已完成
发起方
入组人数
804

研究概览

简要总结

暂无简介。

研究设计

研究类型
Observational

入排标准

性别
All

入选标准

  • Study population 1 (ongoing FLTE MM population):
  • 1. Being on an ongoing frontline therapy line
  • 2. Being considered either fit for transplant at initial diagnosis, or planned on transplant while on frontline therapy, or having already been transplanted while on frontline therapy
  • Study population 2 (previous FLTE MM population):
  • 1. Being on an ongoing relapse or refractory multiple myeloma therapy line
  • 2. Having received a previous frontline therapy line
  • 3. Being considered either fit for transplant at initial diagnosis, or having already been transplanted while on frontline therapy

排除标准

  • Study population 1 (ongoing FLTE MM population):
  • 1. Receiving the ongoing frontline therapy as part of a randomized controlled trial or early access program
  • Study population 2 (previous FLTE MM population):
  • 1. Having initiated the frontline induction prior to 2017

研究者

发起方
Kantar Health (France)

相似试验